Biomerica Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BI</div>
BMRA -- USA Stock  

USD 6.58  0.06  0.90%

While some millenniums are indifferent towards healthcare space, it makes sense to go over Biomerica in terms of its current potentials. As we have suggested previously, Biomerica is beginning its slip as investors shift to be more bearish due to the increased sector volatility. Biomerica barely shadows the market. The returns on investing in Biomerica and the market returns of the last few months appear uncorrelated. Strong technical and fundamental indicators of the company may suggest signs of short-term price drift for investors. Biomerica is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 4th of September 2020.
Published over three weeks ago
View all stories for Biomerica | View All Stories
Is Biomerica (NASDAQ:BMRA) outlook still optimistic?
The company's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Biomerica market sentiment investors' perception of the future value of Biomerica. Let us look at a few aspects of Biomerica technical analysis. About 19.0% of the company shares are held by company insiders. Biomerica recorded a loss per share of 0.27. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 7th of April 2016.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Biomerica. In general, we focus on analyzing Biomerica stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomerica's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Biomerica's intrinsic value. In addition to deriving basic predictive indicators for Biomerica, we also check how macroeconomic factors affect Biomerica price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Biomerica Stands against Peers?

Analyzing Biomerica competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Biomerica across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Biomerica Competition Details

How Biomerica utilizes its cash?

To perform a cash flow analysis of Biomerica, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biomerica is receiving and how much cash it distributes out in a given period. The Biomerica cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Biomerica Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (4.3 Million)

Biomerica exotic insider transaction detected

Legal trades by Biomerica insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biomerica insider trading alert for general transaction of non qualified stock option by Sloan Steven, Chief Financial Officer, on 3rd of September 2020. This event was filed by Biomerica Inc with SEC on 2020-09-03. Initial filing of beneficial ownership - SEC Form 3 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Biomerica Variance

Biomerica has current Variance of 51.18. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Biomerica Variance to its closest peers:

Another setback for Biomerica investors

Current semi deviation is at 5.55. Biomerica is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biomerica independently to ensure intended market timing strategies are aligned with expectations about Biomerica volatility.

Our Final Takeaway

Whereas some firms in the diagnostics & research industry are either recovering or due for a correction, Biomerica may not be performing as strong as the other in terms of long-term growth potentials. To sum up, as of the 31st of August 2020, we believe Biomerica is currently undervalued. It barely shadows the market and projects very low chance of bankruptcy in the next two years. Our primary 30 days buy-hold-sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Biomerica. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to